Entasis: AstraZeneca spinout, based in Waltham, acquired at 60% premium
Entasis Therapeutics, an antibiotics developer that spun out of AstraZeneca plc in 2015, has been acquired by its majority shareholder, California's Innoviva Inc.
Read full article »
Entasis is a biotechnology company that develops and commercializes antibiotic therapies for the treatment of bacterial infections.
Read more